16Nov 2022
Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

To use continuous glucose monitoring (CGM)‐based time‐in‐range (TIR) as a primary efficacy endpoint to compare the second‐generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla‐300) and insulin degludec 100 U/ml (IDeg‐100) in adults with type 1 diabetes (T1D). Overall, 343 participants were randomized: 172 received Gla‐300 and 171 IDeg‐100. Using clinically relevant CGM metrics, InRange shows that Gla‐300 is non‐inferior to IDeg‐100 in people with T1D, with comparable hypoglycaemia and safety profiles.

  • #endo-diabetology

Like

Save

Share